Cell & Gene Therapy Newsletter - December Edition
Welcome to our December Cell & Gene Therapy Roundup!
We’re thrilled to announce that our website now features dedicated pages showcasing all of our CGT solutions. Explore these updates to discover how our comprehensive portfolio can support your journey from research to cure.
Panel discussion:
Unlock the Future of Gene Editing for Successful Payload Strategies
The field of genomics is evolving at lightning speed, and staying informed is more critical than ever. In our latest on-demand video, we bring together industry leaders from big pharma and emerging biotechs for an insightful, informal conversation on the couch.
Register today for this informal, 'on the couch' conversation and stay ahead in the rapidly advancing world of genomics. Don't miss out on this opportunity to enhance your knowledge and drive innovation in your research.
??? Dec 19, 2024 ?? 3 PM London / 10 AM New York
Don't miss out! Register here: https://www.workcast.com/register?cpak=1775419588235200
On-Demand Webinar: GMP Manufacturing of Quality Ancillary Reagents for Cell & Gene Therapy
Missed our live webinar on RegMedNet? Now’s your chance to catch up!
In this insightful session, Dr. Jessie Ni, VP of Product Development, and Bob Schmidt, GMP Bioprocessing Quality Systems Director, explore a risk-based strategy for cell and gene therapy (C>) manufacturers.
Learn how to overcome challenges with ancillary materials to achieve quality, consistency, and safety in your final products.
?? Watch the on-demand webinar now and gain valuable insights to advance your work in cell and gene therapy!
Enhancing Efficiency in Lentivirus Manufacturing for Cell Therapy
Improving the cost and efficiency of lentivirus manufacturing is essential to making cell therapies more accessible.
Recent studies from the University of Manchester and UCL demonstrated that Revvity’s LentiBOOST? transduction enhancer, used with protamine sulfate, can reduce lentiviral vector quantities by nearly 5-fold and cut IMP manufacturing costs.
To further streamline development, scientists are outsourcing to Revvity’s preclinical lentiviral manufacturing services, benefiting from in-house expertise and freeing up resources for core activities.
领英推荐
Explore our Lentivirus manufacturing services
New Blog Post: Overcome AAV Manufacturing Bottlenecks
Discover our latest blog post, "How to Address the Bottlenecks in AAV Manufacturing," which delves into the critical challenges and innovative solutions in the production of adeno-associated virus (AAV) vectors for gene therapy.
Anticipate the Year to Come with Our 2025 Wall Calendar
Over the last two decades, we have provided researchers with comprehensive, cutting-edge, and high-quality reagents for life science research. As a part of Revvity, we aim to continue that tradition while expanding our solutions from research to cure. The stunning fluorescent images that comprise our calendar this year are a collection from our 2024 Image Contest and represent the partnerships we form with scientists. Request a calendar for your lab to look forward to your own discoveries in the new year. Wall calendars are available while supplies last.
Order your free copy: 2025 Wall Calendar
New Application Note: Optimizing Base Editing in T Cells, iPSCs, HSPCs
In our latest application note, we provide valuable insights and recommendations to enhance your gene editing efficiency in critical cell types.
Key highlights of this application note include:
1.??? Comparative analysis of unmodified vs. 5-methyluridine modified mRNAs and specific recommendations for use in T cells, iPSCs, and HSPCs
2.??? Optimization strategies to improve base editing efficiency and cell viability
Disclaimers:
For Research Use Only. Not for use in diagnostic procedures.
Pin-point? base editing reagents are available for research use only and are not for diagnostic use or direct administration into humans or animals.
US Government Supply Contractor at US DOD
2 个月Thanks for sharing. Great info.